Irbesartan Disease Interactions
There are 4 disease interactions with irbesartan.
AR antagonists (applies to irbesartan) hypotension
Major Potential Hazard, High plausibility. Applicable conditions: Dehydration, hemodialysis, Hyponatremia
Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients. Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients). Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable. Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.
AR antagonists (applies to irbesartan) CHF
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure
Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system. In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion. In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death. Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion. In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated. Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.
AR antagonists (applies to irbesartan) hyperkalemia
Moderate Potential Hazard, Moderate plausibility.
Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia. Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia. Use caution when using these agents together and monitor serum potassium periodically.
AR antagonists (applies to irbesartan) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents. Monitor renal function periodically in these patients. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.
Switch to professional interaction data
Irbesartan drug interactions
There are 302 drug interactions with irbesartan.
Irbesartan alcohol/food interactions
There are 2 alcohol/food interactions with irbesartan.
More about irbesartan
- irbesartan consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (109)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- During pregnancy
- Drug class: angiotensin receptor blockers
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Cozaar
Cozaar (losartan) is used to treat high blood pressure (hypertension). Includes Cozaar side ...
Ramipril
Ramipril treats high blood pressure, heart failure, and improves survival after a heart attack ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Benazepril
Benazepril systemic is used for diabetic kidney disease, heart failure, high blood pressure, left ...
Lisinopril
Lisinopril is an ACE inhibitor. It is used to treat high blood pressure, congestive heart failure ...
Lasix
Lasix is a loop diuretic used to treat fluid retention from heart, liver, or kidney conditions, and ...
Captopril
Captopril is used to treat hypertension, heart failure and to improve survival after a heart ...
Avapro
Avapro (irbesartan) is used to treat high blood pressure and kidney problems caused by diabetes ...
Hydrochlorothiazide
HCTZ (hydrochlorothiazide) used to treat high blood pressure (hypertension) and edema. Includes ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.